• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠道通透性在肝损伤发病机制中的作用:从非酒精性脂肪性肝病到肝移植。

Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation.

机构信息

Fondazione Policlinico Universitario A Gemelli IRCCS, Rome 00168, Italy.

出版信息

World J Gastroenterol. 2019 Sep 7;25(33):4814-4834. doi: 10.3748/wjg.v25.i33.4814.

DOI:10.3748/wjg.v25.i33.4814
PMID:31543676
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6737313/
Abstract

The intimate connection and the strict mutual cooperation between the gut and the liver realizes a functional entity called gut-liver axis. The integrity of intestinal barrier is crucial for the maintenance of liver homeostasis. In this mutual relationship, the liver acts as a second firewall towards potentially harmful substances translocated from the gut, and is, in turn, is implicated in the regulation of the barrier. Increasing evidence has highlighted the relevance of increased intestinal permeability and consequent bacterial translocation in the development of liver damage. In particular, in patients with non-alcoholic fatty liver disease recent hypotheses are considering intestinal permeability impairment, diet and gut dysbiosis as the primary pathogenic trigger. In advanced liver disease, intestinal permeability is enhanced by portal hypertension. The clinical consequence is an increased bacterial translocation that further worsens liver damage. Furthermore, this pathogenic mechanism is implicated in most of liver cirrhosis complications, such as spontaneous bacterial peritonitis, hepatorenal syndrome, portal vein thrombosis, hepatic encephalopathy, and hepatocellular carcinoma. After liver transplantation, the decrease in portal pressure should determine beneficial effects on the gut-liver axis, although are incompletely understood data on the modifications of the intestinal permeability and gut microbiota composition are still lacking. How the modulation of the intestinal permeability could prevent the initiation and progression of liver disease is still an uncovered area, which deserves further attention.

摘要

肠道和肝脏之间的密切联系和严格的相互合作实现了一个功能实体,称为肠肝轴。肠道屏障的完整性对于维持肝脏内环境稳定至关重要。在这种相互关系中,肝脏作为从肠道易位的潜在有害物质的第二道防火墙,反过来又参与了屏障的调节。越来越多的证据强调了肠道通透性增加和随之而来的细菌易位在肝损伤发展中的相关性。特别是在非酒精性脂肪性肝病患者中,最近的假说认为肠道通透性损害、饮食和肠道菌群失调是主要的致病触发因素。在晚期肝病中,门静脉高压会增强肠道通透性。其临床后果是细菌易位增加,进一步加重肝损伤。此外,这种致病机制与大多数肝硬化并发症有关,如自发性细菌性腹膜炎、肝肾综合征、门静脉血栓形成、肝性脑病和肝细胞癌。肝移植后,门静脉压力的降低应该对肠肝轴产生有益的影响,但关于肠道通透性和肠道微生物群组成的改变的数据仍不完全了解。肠道通透性的调节如何预防肝病的发生和进展仍然是一个未被揭示的领域,值得进一步关注。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/294e/6737313/a393d49f0642/WJG-25-4814-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/294e/6737313/b8e748cfeda1/WJG-25-4814-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/294e/6737313/a393d49f0642/WJG-25-4814-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/294e/6737313/b8e748cfeda1/WJG-25-4814-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/294e/6737313/a393d49f0642/WJG-25-4814-g002.jpg

相似文献

1
Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation.肠道通透性在肝损伤发病机制中的作用:从非酒精性脂肪性肝病到肝移植。
World J Gastroenterol. 2019 Sep 7;25(33):4814-4834. doi: 10.3748/wjg.v25.i33.4814.
2
Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.肠-肝轴、肝硬化和门静脉高压:先有鸡还是先有蛋。
Hepatol Int. 2018 Feb;12(Suppl 1):24-33. doi: 10.1007/s12072-017-9798-x. Epub 2017 May 26.
3
Gut-liver axis signaling in portal hypertension.门脉高压症中的肠道-肝脏轴信号。
World J Gastroenterol. 2019 Oct 21;25(39):5897-5917. doi: 10.3748/wjg.v25.i39.5897.
4
Potential mechanisms linking gut microbiota and portal hypertension.肠道微生物群与门静脉高压相关的潜在机制。
Liver Int. 2019 Apr;39(4):598-609. doi: 10.1111/liv.13986. Epub 2018 Nov 9.
5
Liver cirrhosis and complications from the perspective of dysbiosis.从菌群失调角度看肝硬化及其并发症
Front Med (Lausanne). 2024 Jan 16;10:1320015. doi: 10.3389/fmed.2023.1320015. eCollection 2023.
6
Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.综述文章:肠道微生物组作为慢性肝病发病机制和治疗的治疗靶点。
Aliment Pharmacol Ther. 2018 Jan;47(2):192-202. doi: 10.1111/apt.14397. Epub 2017 Oct 30.
7
Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD.缺乏 NLRP3 炎性小体导致 NAFLD 小鼠模型的肠道-肝脏轴紊乱、肠道菌群失调和表型恶化。
Sci Rep. 2017 Sep 22;7(1):12200. doi: 10.1038/s41598-017-11744-6.
8
Gut microbiota-related complications in cirrhosis.肝硬化中与肠道微生物群相关的并发症。
World J Gastroenterol. 2014 Nov 14;20(42):15624-31. doi: 10.3748/wjg.v20.i42.15624.
9
Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease.非甾体抗炎药对肠道通透性和非酒精性脂肪性肝病的作用
World J Gastroenterol. 2017 Jun 14;23(22):3954-3963. doi: 10.3748/wjg.v23.i22.3954.
10
FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.FXR 通过调节实验性肝硬化中细菌易位的进入部位来调节肠道-血管屏障。
J Hepatol. 2019 Dec;71(6):1126-1140. doi: 10.1016/j.jhep.2019.06.017. Epub 2019 Jul 8.

引用本文的文献

1
Pathogenesis and Clinical Management of Metabolic Dysfunction-Associated Steatotic Liver Disease.代谢功能障碍相关脂肪性肝病的发病机制与临床管理
Int J Mol Sci. 2025 Jun 14;26(12):5717. doi: 10.3390/ijms26125717.
2
Betaine regulates the gut-liver axis: a therapeutic approach for chronic liver diseases.甜菜碱调节肠-肝轴:一种慢性肝病的治疗方法。
Front Nutr. 2025 Mar 24;12:1478542. doi: 10.3389/fnut.2025.1478542. eCollection 2025.
3
Small Intestinal Bacterial Overgrowth Is a Predictor of Overt Hepatic Encephalopathy in Patients with Liver Cirrhosis.

本文引用的文献

1
Lipopolysaccharide induces the differentiation of hepatic progenitor cells into myofibroblasts constitutes the hepatocarcinogenesis-associated microenvironment.脂多糖诱导肝祖细胞分化为肌成纤维细胞构成与肝癌发生相关的微环境。
Cell Death Differ. 2020 Jan;27(1):85-101. doi: 10.1038/s41418-019-0340-7. Epub 2019 May 7.
2
A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma.不同的肠道微生物组与伴有和不伴有肝细胞癌的肝硬化患者的炎症有关。
Ann Hepatol. 2019 May-Jun;18(3):480-487. doi: 10.1016/j.aohep.2018.10.003. Epub 2019 Apr 15.
3
Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease.
小肠细菌过度生长是肝硬化患者显性肝性脑病的一个预测指标。
J Clin Med. 2025 Feb 23;14(5):1491. doi: 10.3390/jcm14051491.
4
Carotenoids Improve Obesity and Fatty Liver Disease via Gut Microbiota: A Narrative Review.类胡萝卜素通过肠道微生物群改善肥胖和脂肪性肝病:一篇叙述性综述。
Food Sci Nutr. 2025 Mar 10;13(3):e70092. doi: 10.1002/fsn3.70092. eCollection 2025 Mar.
5
The synergistic role of gut microbiota and RNA in metabolic diseases: mechanisms and therapeutic insights.肠道微生物群与RNA在代谢性疾病中的协同作用:机制与治疗见解
Front Microbiol. 2025 Jan 29;16:1504395. doi: 10.3389/fmicb.2025.1504395. eCollection 2025.
6
sp. for the Attenuation of Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice.用于减轻小鼠代谢功能障碍相关脂肪性肝病的物种。
Microorganisms. 2024 Dec 3;12(12):2488. doi: 10.3390/microorganisms12122488.
7
Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease.以微生物群为中心的代谢功能障碍相关脂肪性肝病治疗方法
Clin Mol Hepatol. 2025 Feb;31(Suppl):S94-S111. doi: 10.3350/cmh.2024.0811. Epub 2024 Nov 28.
8
Bacterial contamination of autologous blood salvaged during deceased donor liver transplantation: a prospective observational study.在尸体供肝移植期间回收的自体血的细菌污染:一项前瞻性观察研究。
Sci Rep. 2024 Nov 5;14(1):26785. doi: 10.1038/s41598-024-76476-w.
9
Interplay among IL1R1, gut microbiota, and bile acids in metabolic dysfunction-associated steatotic liver disease: a comprehensive review.白细胞介素1受体1、肠道微生物群和胆汁酸在代谢功能障碍相关脂肪性肝病中的相互作用:综述
J Gastroenterol Hepatol. 2025 Jan;40(1):33-40. doi: 10.1111/jgh.16750. Epub 2024 Sep 29.
10
Impact of High-Temperature Feeds on Gut Microbiota and MAFLD.高温饲料对肠道微生物群和 MAFLD 的影响。
J Microbiol Biotechnol. 2024 Sep 28;34(9):1789-1802. doi: 10.4014/jmb.2405.05023. Epub 2024 Jul 31.
非酒精性脂肪肝患者采用地中海饮食和低脂饮食后的肠道通透性。
World J Gastroenterol. 2019 Jan 28;25(4):509-520. doi: 10.3748/wjg.v25.i4.509.
4
Potential mechanisms linking gut microbiota and portal hypertension.肠道微生物群与门静脉高压相关的潜在机制。
Liver Int. 2019 Apr;39(4):598-609. doi: 10.1111/liv.13986. Epub 2018 Nov 9.
5
Gut inflammation exacerbates hepatic injury in the high-fat diet induced NAFLD mouse: Attention to the gut-vascular barrier dysfunction.肠道炎症加重高脂肪饮食诱导的非酒精性脂肪性肝病小鼠的肝损伤:关注肠道-血管屏障功能障碍。
Life Sci. 2018 Sep 15;209:157-166. doi: 10.1016/j.lfs.2018.08.017. Epub 2018 Aug 7.
6
Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications.肝硬化患者的细菌易位:生理学、临床后果及实际意义。
Expert Rev Gastroenterol Hepatol. 2018 Jul;12(7):641-656. doi: 10.1080/17474124.2018.1481747. Epub 2018 Jun 6.
7
Targeting Oxidative Stress for the Treatment of Liver Fibrosis.靶向氧化应激治疗肝纤维化。
Rev Physiol Biochem Pharmacol. 2018;175:71-102. doi: 10.1007/112_2018_10.
8
Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.肝细胞癌与非酒精性脂肪性肝病中的肠道微生物群特征和炎症有关。
Hepatology. 2019 Jan;69(1):107-120. doi: 10.1002/hep.30036. Epub 2018 Jul 10.
9
Maintenance of intestinal homeostasis by mucosal barriers.黏膜屏障对肠道内稳态的维持。
Inflamm Regen. 2018 Apr 2;38:5. doi: 10.1186/s41232-018-0063-z. eCollection 2018.
10
High MUC2 Mucin Expression and Misfolding Induce Cellular Stress, Reactive Oxygen Production, and Apoptosis in Goblet Cells.高表达的 MUC2 粘蛋白和错误折叠诱导杯状细胞发生细胞应激、活性氧产生和凋亡。
Am J Pathol. 2018 Jun;188(6):1354-1373. doi: 10.1016/j.ajpath.2018.02.007. Epub 2018 Mar 12.